Insulet (PODD) Aktsia Kursus
Insulet Kursus
Käive kasvas 41,6 % aastas viimase 19 aasta jooksul 2,71 B USD-ni. Kasum aktsia kohta kasvas 81,5 % aastas viimase 7 aasta jooksul. Insulet netomarginaal on nüüd 9,1 %, tõusnud 1,5 %-lt mõni aasta tagasi. Analüütikute hinnasihi mediaan on 180,00 USD, st üle praegust hinda 26,3 %. 33 analüütikust 20 soovitab osta — üldine konsensus on Osta.
Insulet aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Insulet ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Insulet aktsia kohta
The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.
Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.
The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.
Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.
Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.
Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.
Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.
Analüütikud määravad Insulet aktsiale keskmiseks hinnasihi 185,18 USD (mediaan: 180,00 USD), mis on +29,9 % viimase hinna suhtes. Konsensus põhineb 33 analüütiku hinnangul.
33 analüütikut hindavad praegu Insulet aktsiat: 20 soovitab osta, 13 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Insulet teenib tulu 3,29 B USD ja kasumit aktsia kohta 6,62 USD.
Praeguse kursiga kaubeldakse Insulet aktsiaga 126,78 EUR (142,51 USD) juures.
Insulet aktsia (PODD) on noteeritud 5 börsil, sh: NASDAQ (PODD), SIX (Zürich) (GOV.SW), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU).
Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.
oodatav Insulet käive on 3,29 B USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Insulet kasum on 467,48 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Insulet jaoks on praegu 21,54. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Insulet aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Insulet jaoks on praegu 3,06. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Insulet aktsia jaoks.
Eulpooli kvaliteedinäitaja Insulet jaoks on 6/10.
Insulet ISIN on US45784P1012. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Insulet WKN on A0MQX8. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Insulet ticker on PODD. Ticker-sümbol kasutatakse Insulet aktsiate kauplemiseks börsil.
Insulet aktsia
Insulet konkurendid
Insulet Börsiticker
Insulet FIGI
Kõik teised näitajad ja analüüsid Insulet kohta sügavamalt
Meie Insulet-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Insulet. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: